⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22529636 | 1.00 | — | — | |
| SCHEMBL1564431 | 0.76 | — | — | |
| SCHEMBL8997410 | 0.75 | — | — | |
| SCHEMBL2186368 | 0.75 | — | — | |
| SCHEMBL3346843 | 0.73 | — | — | |
| SCHEMBL11269 | 0.70 | — | — | |
| SCHEMBL321501 | 0.70 | — | — | |
| SCHEMBL863536 | 0.68 | — | — | |
| SCHEMBL2306505 | 0.68 | — | — | |
| SCHEMBL2304373 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | claimed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-115279750-B | GLP-1 receptor agonist, pharmaceutical composition containing same and preparation method thereof | 株式会社LG化学 | 2024-06-21 | — | — | CN | claimed |
| CN-115461334-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | claimed |
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | claimed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | claimed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| WO-2024063140-A1 | MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | 塩野義製薬株式会社 | 2024-03-28 | — | — | WO | claimed |
| WO-2024063143-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | 塩野義製薬株式会社 | 2024-03-28 | — | — | WO | claimed |
| EP-0364797-B1 | N-aryl-nitrogenated heterocycles, process for their preparation and their use as herbicides | BAYER AG (DE) | 1994-02-16 | — | — | EP | claimed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | claimed |
| US-5221318-A | Crop plant selectivity | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | claimed |
| US-5108483-A | HERBICIDAL 6-HETEROCYCLIC GROUP SUBSTITUTED BENZOXAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-28 | — | — | US | claimed |
| EP-0473387-A2 | Anti-fungal triazole derivatives, their preparation and uses | Sankyo Company Limited (JP) | 1992-03-04 | — | — | EP | claimed |
| US-5069711-A | PREEMERGENCE | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | claimed |
| EP-0427031-A2 | N-aryl-nitrogen heterocycles | BAYER AG (DE) | 1991-05-15 | — | — | EP | claimed |
| EP-0416361-A1 | N-(5-alkyl thiophenyl)-nitrogenheterocycles | BAYER AG (DE) | 1991-03-13 | — | — | EP | claimed |
| EP-0400403-A2 | N-aryl-nitrogen-heterocycles | BAYER AG (DE) | 1990-12-05 | — | — | EP | claimed |
| EP-0364797-A2 | N-aryl-nitrogenated heterocycles, process for their preparation and their use as herbicides | BAYER AG (DE) | 1990-04-25 | — | — | EP | claimed |